Drugs · acquisition-cost intelligence
Dexmethylphenidate hydrochloride
· ingredient dexmethylphenidate· DEXMETHYLPHENIDATE HYDROCHLORIDE 25 mg/1; DEXMETHYLPHENIDATE HYDROCHLORIDE 35 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$2.08
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other dexmethylphenidate products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Focalin | $0.31366 | −$1.77 |
| Dexmethylphenidate Hydrochloride Extended-Release | $1.28 | −$0.80290 |
| Dexmethylphenidate Hydrochloride Extended-Release | $1.93 | −$0.14840 |
Medicare Part D coverage · CY2026
On 55 plan formularies · typical tier 4
Prior auth 2% · Step therapy 0% · Quantity limit 82% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.